GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

Today
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Dr Agarwals Eye Hospital Ltd-$
Unaudited Financial Results for the quarter ended June 30, 2026, is submitted.
RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 03 Aug 2026, 05:33 PM IST  ·  BSE ID: 9eb893a5-8cb7-4c0f-a1cb-9eb44810ef48
View Original BSE Filing (PDF)
💡
In Simple Terms
Dr. Agarwals Eye Hospital reported first-quarter revenue of INR 142.97 Crores and a net profit of INR 23.38 Crores.
🤖 AI Summary
  • Revenue from operations reached INR 142.97 Crores for the quarter ended June 30, 2026.
  • Net profit after tax for Q1 FY27 was INR 23.38 Crores.
  • Basic Earnings per Share (EPS) for the quarter stood at INR 48.38.
  • M/s. B Y & Associates re-appointed as Cost Auditors for the financial year 2026-27.
  • Proposed scheme of amalgamation with Dr. Agarwal's Health Care Limited approved by shareholders, awaiting NCLT sanction.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Quarter ended June 30, 2026)
142.97 INR Crores
22.28%
Net profit after tax (Quarter ended June 30, 2026)
23.38 INR Crores
35.46%
Basic Earnings per equity share (Quarter ended June 30, 2026)
48.38 INR
31.74%
Total expenses (Quarter ended June 30, 2026)
113.97 INR Crores
20.57%
EBITDA (Quarter ended June 30, 2026)
45.22 INR Crores
19.22%
🏢 How This Affects the Company
📈
Business Impact
The company's revenue from operations increased to INR 142.97 Crores for the quarter, reflecting continued operational activity in eye care services.
💰
Financial Impact
Net profit after tax improved to INR 23.38 Crores, with an EBITDA of INR 45.22 Crores, indicating sustained profitability for the period.
⚙️
Operational Impact
The re-appointment of Cost Auditors ensures ongoing compliance with Section 148 of the Companies Act, 2013, regarding cost record audits for FY2026-27.
⚠️
Risk Impact
The ongoing scheme of amalgamation with Dr. Agarwal's Health Care Limited remains subject to final sanction from the Hon'ble NCLT, which presents a pending regulatory approval step.
👥 What This Means For Shareholders
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with the Basic EPS for Q1 FY27 reported at INR 48.38.
🔍
Management Signal
The Board's approval of the unaudited financial results and re-appointment of Cost Auditors indicates adherence to regulatory compliance and ongoing business operations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
NCLT decision on amalgamation with Dr. Agarwal's Health Care Limited.
Q2 FY27 unaudited financial results for revenue and profit trends.
Completion of Cost Audit for financial year 2026-27.
LOW RISK The financial results indicate stable performance. The primary pending item is regulatory approval for amalgamation.
💡 Investor Takeaway
Dr. Agarwals Eye Hospital reported Q1 FY27 revenue from operations of INR 142.97 Crores and a net profit after tax of INR 23.38 Crores. This represents a 22.28% increase in revenue and 35.46% increase in net profit YoY, reflecting growth in the period.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations increased by INR 26.05 Crores to INR 142.97 Crores in Q1 FY27 compared to INR 116.92 Crores in Q1 FY26.
  • Net profit after tax rose by INR 6.12 Crores to INR 23.38 Crores in Q1 FY27, from INR 17.26 Crores in Q1 FY26.

⚠️ Concerns

  • Finance costs increased to INR 2.77 Crores in Q1 FY27, compared to INR 1.96 Crores in the preceding quarter (Q4 FY26).
  • Other expenses grew to INR 22.42 Crores in Q1 FY27, up from INR 16.08 Crores in the corresponding quarter of the previous year (Q1 FY26).
📅 Company Track Record
Previous filings indicated a Board meeting on August 03, 2026, to approve Q1 FY27 unaudited financial results, which has now been completed. The scheme of amalgamation with Dr. Agarwal's Health Care Limited was approved by the Board on August 27, 2025, and by shareholders on July 02, 2026, as noted in the results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Dr. Agarwals Eye Hospital's revenue from operations for the quarter ended June 30, 2026?
Dr. Agarwals Eye Hospital reported revenue from operations of INR 142.97 Crores for the quarter ended June 30, 2026.
What was the net profit after tax for Dr. Agarwals Eye Hospital in Q1 FY27?
The net profit after tax for Dr. Agarwals Eye Hospital for the quarter ended June 30, 2026, was INR 23.38 Crores.
What was the Basic EPS of Dr. Agarwals Eye Hospital for the quarter ended June 30, 2026?
The Basic Earnings per Equity Share for Dr. Agarwals Eye Hospital for the quarter ended June 30, 2026, was INR 48.38.
Which firm was re-appointed as the Cost Auditors for Dr. Agarwals Eye Hospital for FY2026-27?
M/s. B Y & Associates, Practicing Cost Accountants, were re-appointed as the Cost Auditors for Dr. Agarwals Eye Hospital for the financial year 2026-27.
What is the status of the amalgamation scheme with Dr. Agarwal's Health Care Limited?
The amalgamation scheme with Dr. Agarwal's Health Care Limited was approved by shareholders on July 02, 2026, and remains subject to final sanction from the Hon'ble NCLT.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.